2018

1. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

   Haematologica, Vol. 103, Núm. 9, pp. 1518-1526